Won-Gil Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10535888/publications.pdf

Version: 2024-02-01

16	336	933447 10	996975 15
papers	citations	h-index	g-index

17	17	17	416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structural investigation of <scp>2â€naphthyl</scp> phenyl ether inhibitors bound to <scp>WT</scp> and <scp>Y181C</scp> reverse transcriptase highlights key features of the <scp>NNRTI</scp> binding site. Protein Science, 2020, 29, 1902-1910.	7.6	7
2	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2182-2188.	2.2	4
3	From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E802-E811.	7.1	30
4	Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8114-E8115.	7.1	0
5	Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Molecular Pharmacology, 2017, 91, 383-391.	2.3	14
6	Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9725-9730.	7.1	43
7	Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents. ACS Medicinal Chemistry Letters, 2016, 7, 1156-1160.	2.8	22
8	Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4824-4827.	2.2	19
9	Discovery of novel purine-based heterocyclic P2X7 receptor antagonists. Bioorganic Chemistry, 2015, 61, 58-65.	4.1	1
10	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. ACS Medicinal Chemistry Letters, 2015, 6, 1075-1079.	2.8	22
11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers. ACS Medicinal Chemistry Letters, 2014, 5, 1259-1262.	2.8	39
12	Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group. Journal of the American Chemical Society, 2013, 135, 16705-16713.	13.7	78
13	Structureâ€“Activity Relationships and Optimization of 3,5-Dichloropyridine Derivatives As Novel P2X₇ Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 3687-3698.	6.4	24
14	Immunosuppressive Effects of Subglutinol Derivatives. ChemMedChem, 2012, 7, 218-222.	3.2	9
15	Characterization of protoberberine analogs employed as novel human P2X7 receptor antagonists. Toxicology and Applied Pharmacology, 2011, 252, 192-200.	2.8	7
16	Synthesis and biological evaluation of Î±,Î²-unsaturated lactones as potent immunosuppressive agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5726-5729.	2.2	17